Bio-Rad Laboratories, Inc. recently completed the acquisition of AbD Serotec, formerly a division of MorphoSys AG. Bio-Rad has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, and major research institutions as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service.
The acquisition of AbD Serotec will enhance both Bio-Rad’s Life Science Research line and its Clinical Diagnostic products. Bio-Rad also completed a licensing agreement with MorphoSys to use its HuCAL® human combinatorial antibody library technology for diagnostic and research purposes.
Following this acquisition, Bio-Rad will have access to a comprehensive catalog of antibodies, enabling the validation of total assay solutions on Bio-Rad’s research platforms for the western blotting, multiplex protein expression, ELISA, and cell sorting product lines. Exploiting this powerful in vitro technology will accelerate future antibody generation.
Learn more about Bio-Rad products and services by following the links below.